REGNR8™ · Investor legal & disclosures

Clear boundaries for health, investment and controlled diligence.

Review-draft disclosure structure. Professional legal, securities, privacy, valuation and owner approval is required before live fundraising publication.

01

Health disclaimer

REGNR8 provides educational, interpretive and coaching-support infrastructure. It does not diagnose, prescribe, treat, cure, prevent disease, change medication, replace qualified care or provide emergency support. Product demonstrations use synthetic or properly de-identified material and must not be used for clinical decision-making.

02

Investor / securities disclaimer

The website is for general information and controlled or confidential investor discussion only. It is not investment, legal, tax, accounting or medical advice and does not guarantee product performance or investor return.

03

Forward-looking statements

Plans, milestones, markets, product development, pilots, revenue assumptions, financing, corporate structure and future performance are uncertain and subject to risk. Actual outcomes may differ materially.

04

No offer / no solicitation

Public pages and expressions of interest do not constitute an offer, solicitation, allocation, reservation or right to participate. Securities processes are subject to applicable law and definitive documentation.

05

No investment advice

Prospective investors should conduct their own diligence and obtain independent legal, tax, accounting and investment advice.

06

Early-stage risk

Early-stage participation may involve technical, market, regulatory, classification, privacy, funding, dilution, key-person, competition, corporate-structure and illiquidity risks, including the possibility of loss of all capital committed.

07

Valuation boundary

If USD $24M appears on investor pages, it is identified only as a management pre-money fundraising anchor for discussion. It is not a certified valuation, independent valuation opinion, fair-market-value determination, securities-law conclusion, investment recommendation or guarantee of future value.

09

Demo materials

Demonstrations are illustrative and non-clinical and use synthetic or properly de-identified information. They are not evidence of clinical efficacy, diagnostic accuracy, commercial adoption or guaranteed performance.

10

Confidential investor materials

Confidential materials may be restricted, watermarked, access-logged and subject to NDA, relevance checks, investor-status review and management approval. Access does not create an offer, allocation or entitlement.

11

Jurisdictional limits

Any potential investment depends on applicable law, investor eligibility and jurisdiction. No person should access or act on investor information where doing so would breach applicable law.

12

Corporate structure

The current investment entity is Executive Athlete Lab (Pty) Ltd, subject to definitive legal documentation. Any future restructuring, including a possible Delaware parent, is conditional on commercial requirements, lawful implementation and professional advice.

Controlled review draft

This page provides a disclosure architecture for review and is not a substitute for jurisdiction-specific legal and securities advice.